




RESEARCH PAPER



Exploring new structural features of the 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamide scaffold for the inhibition of human carbonic anhydrases

Simona Distinto^a , Rita Meleddu^a , Francesco Ortuso^b , Filippo Cottiglia^a, Serenella Deplano^a, Lisa Sequeira^a , Claudia Melis^a, Benedetta Fois^a, Andrea Angeli^c , Clemente Capasso^d , Rossella Angius^e, Stefano Alcaro^b , Claudiu T. Supuran^c  and Elias Maccioni^a 

^aDepartment of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy; ^bDipartimento di Scienze della Salute, Università Magna Graecia di Catanzaro, Catanzaro, Italy; ^cDipartimento NEUROFARBA, Sezione di Scienze Farmaceutiche, Università degli Studi di Firenze, Sesto Fiorentino, Italy; ^dIstituto di Bioscienze e Biorisorse, CNR, Napoli, Italy; ^eLaboratorio NMR e Tecnologie Bioanalitiche, Pula, Italy

ABSTRACT

A library of 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzene-1-sulphonamides (**EMAC8002a–m**) was designed and synthesised to evaluate the effect of substituents in the positions 3 and 4 of the dihydrothiazole ring on the inhibitory potency and selectivity toward human carbonic anhydrase isoforms I, II, IX, and XII. Most of the new compounds preferentially inhibit the isoforms II and XII. Both electronic and steric features on the aryl substituent in the position 4 of the dihydrothiazole ring concur to determine the overall biological activity of these new derivatives.

ARTICLE HISTORY

Received 18 June 2019
Revised 5 August 2019
Accepted 6 August 2019

KEYWORDS

Antitumour agents;
carbonic anhydrase
inhibitors; dihydrothiazoles;
sulphonamide

Introduction

1,3-thiazole and their hydrogenated analogues are important molecular subunits in diverse classes of biologically active molecules and thus can be found in several drugs approved for clinical use. Not surprisingly, this moiety has been extensively studied and both natural and synthetic thiazole derivatives are in therapeutic use or have shown potential therapeutic application toward several pathologies and targets such as bacteria^{1,2}, tumours^{3–6}, HIV-1 protease and reverse transcriptase^{7–12}, fungi^{13–15}, neurodegeneration and related pathologies^{12,16,17}, and protozoal infections¹⁸. Recently, we reported on benzenesulphonamide dihydrothiazole derivatives as inhibitors of human carbonic anhydrase (hCA) isoforms I, II, IX, and XII¹⁹. This enzyme family catalyses the reversible hydration of carbon dioxide to bicarbonate and protons¹⁹ and, therefore, plays an essential role in CO₂-related metabolism and in its transportation across biological membranes^{20,21}. Due to their simple but essential role, hCAs have been recognised as main actors in a number of physiological processes and pathologies^{22–30}. Not surprisingly, hCA inhibitors have been intensively studied and several are in clinical use for diverse pathologies^{31–37}. Although different mechanisms of inhibition of hCA have been reported (e.g. coumarins, phenols, primary amines, COOMe derivatives)^{38–42}, benzenesulphonamides and their isomers are the most represented molecular class of inhibitors^{32,43–48}. These inhibitors belong to the so called zinc binders. They bind the zinc cofactor as conjugated bases and therefore, the acidity of the sulphonamide group influences their potency. Thus, by conjugating the benzenesulphonamide group to an electron withdrawing





heterocyclic ring, the activity could be favourably influenced. Moreover, the introduction of further substituents in the heterocyclic core may influence the isozyme selectivity. On these bases, and according to our previous observation^{31,47–50}, we have synthesised and evaluated for the inhibition activity toward hCA I, II, IX, and XII isoforms a series of the 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamides (Figure 1).

Methods

Materials and apparatus

Starting materials and reagents were obtained from commercial suppliers and were used without purification. All melting points were determined on a Stuart SMP11 melting points apparatus and are uncorrected. Electron ionisation mass spectra were obtained by a Fisons QMD 1000 mass spectrometer (Danvers, MA) (70 eV, 200 mA, ion source temperature 200 °C). Samples were directly introduced into the ion source. Melting points, yield of reactions, and analytical data of derivatives **EMAC8002a–I** are reported in Table 1.

¹H-NMR (Table 2) were registered on a Bruker AMX (300 MHz) (chemical shifts in δ values) or on a Unity Inova 500NB high-resolution spectrometer (Agilent Technologies, CA) (500 MHz) All samples were measured in DMSO. Chemical shifts are reported referenced to the solvent in which they were measured. Coupling constants *J* are expressed in hertz (Hz). Elemental analyses were obtained on a Perkin–Elmer 240 B microanalyser. Analytical data

CONTACT Claudiu T. Supuran  claudiu.supuran@unifi.it  Dipartimento NEUROFARBA, Sezione di Scienze Farmaceutiche, Università degli Studi di Firenze, Sesto Fiorentino, Florence, Italy; Rita Meleddu  rita.meleddu@unica.it  Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.




Figure 1. Carbonic anhydrase inhibitors in clinical use and previously reported EMAC derivatives: (1) acetazolamide (2) ethoxzolamide, (3) dichlorphenamide, (4) dorzolamide, (5) EMAC10020⁴⁷, (6) EMAC8001³¹, (7) EMAC8000⁴⁸, (8) EMAC10153⁵⁰, (9) EMAC10111⁴⁹.

Table 1. Chemical, analytical, and physical data of derivatives EMAC8002 a–m.

| Compound | R | R.F. ^a | C–H–N | | M.P. °C | Yield % | Mass fragments |
|-----------|---------------------------------|-------------------|------------------------------|------------------------------|---------|---------|----------------|
| | | | Calc. | Found | | | |
| EMAC8002a | 4-Br | 0.78 | C, 45.29; H, 3.33; N, 9.90 | C, 44.87; H, 3.28; N, 9.83 | 256-259 | 55 | 425; 423 |
| EMAC8002b | 4-Cl | 0.70 | C, 50.59; H, 3.71; N, 11.06 | C, 50.61; H, 3.67; N, 11.02 | 241-242 | 76 | 379 |
| EMAC8002c | 4-F | 0.63 | C, 52.88; H, 3.88; N, 11.56 | C, 52.90; H, 3.83; N, 11.51 | 230-233 | 58 | 363 |
| EMAC8002d | 3-NO ₂ | 0.74 | C, 49.22; H, 3.61; N, 14.35; | C, 49.30; H, 3.58; N, 14.28; | 235-236 | 73 | 390 |
| EMAC8002e | 2,4-Cl | 0.83 | C, 46.38; H, 3.16; N, 10.14 | C, 46.42; H, 3.13; N, 10.09 | 256-257 | 79 | 413 |
| EMAC8002f | 4-CN | 0.72 | C, 55.12; H, 3.81; N, 15.12 | C, 55.08; H, 3.77; N, 15.04 | 237-238 | 85 | 370 |
| EMAC8002g | 2,4-F | 0.67 | C, 50.38; H, 4.44; N, 11.02 | C, 50.31; H, 4.40; N, 10.97 | 239-240 | 45 | 381 |
| EMAC8002h | 4-NO ₂ | 0.72 | C, 49.22; H, 3.61; N, 14.35 | C, 49.00; H, 3.58; N, 14.29 | 244-245 | 63 | 390 |
| EMAC8002i | 4-C ₆ H ₅ | 0.76 | C, 62.68; H, 4.54; N, 9.97 | C, 62.68; H, 4.52; N, 9.98 | 254-255 | 72 | 421 |
| EMAC8002j | 4-CH ₃ | 0.77 | C, 56.80; H, 4.77; N, 11.69 | C, 56.75; H, 4.80; N, 11.61 | 252-254 | 67 | 359 |
| EMAC8002k | 4-OCH ₃ | 0.65 | C, 54.38; H, 4.56; N, 11.19 | C, 54.37; H, 4.57; N, 11.17 | 243-244 | 77 | 375 |
| EMAC8002l | // | 0.69 | C, 47.84; H, 3.73; N, 11.96 | C, 47.80; H, 3.75; N, 11.89 | 233-235 | 74 | 351 |
| EMAC8002m | H | 0.74 | C, 55.63; H, 4.38; N, 12.16 | C, 55.55; H, 4.34; N, 12.13 | 252-253 | 67 | 345 |

^aR.F. values were obtained on silica gel plates using a mixture of ethyl acetate/n-hexane 2/1.

Table 2. ¹H NMR data of derivatives EMAC8002a–m.

| Compound | ¹ H NMR δ (ppm) |
|-----------|--|
| EMAC8002a | ¹ H-NMR: (300 MHz, DMSO) 3.57 (3H, s, CH ₃), 7.10 (1H, s, CH thiazole), 7.45 (2H, s, NH ₂ , D ₂ O), 7.54 (2H, d, <i>J</i> = 7.9 Hz, CH Ar), 7.61 (2H, d, <i>J</i> = 7.7 Hz, CH Ar), 7.78 (2H, d, <i>J</i> = 7.8 Hz, CH Ar), 7.95 (2H, d, <i>J</i> = 7.7 Hz, CH Ar) |
| EMAC8002b | ¹ H-NMR: (300 MHz, DMSO) 3.46 (3H, s, CH ₃), 6.83 (1H, s, CH thiazole), 7.36 (2H, s, NH ₂ , D ₂ O), 7.44 (2H, d, <i>J</i> = 8.4 Hz, CH Ar), 7.58 (2H, d, <i>J</i> = 8.7 Hz, CH Ar), 7.63 (2H, d, <i>J</i> = 8.4 Hz, CH Ar), 7.88 (2H, d, <i>J</i> = 8.5 Hz, CH Ar) |
| EMAC8002c | ¹ H-NMR: (300 MHz, DMSO) 3.65 (3H, s, CH ₃), 7.01 (1H, s, CH thiazole), 7.50 (2H, t, <i>J</i> = 8.5 Hz, CH Ar), 7.56 (2H, s, NH ₂ , D ₂ O), 7.67 (2H, d, <i>J</i> = 8.7 Hz, CH Ar), 7.74 (2H, dd, <i>J</i> _{H-H} : 8.5, <i>J</i> _{H-F} : 5.5, CH Ar), 8.02 (2H, d, <i>J</i> = 9.0, CH Ar) |
| EMAC8002d | ¹ H-NMR: (300 MHz, DMSO) NH ₂ not detected, 3.34 (3H, s, CH ₃), 6.59 (1H, s, CH thiazole), 7.18 (2H, d, <i>J</i> = 8.5 Hz, CH Ar), 7.24 (1H, s, CH Ar), 7.78 (2H, d, <i>J</i> = 8.5 Hz, CH Ar), 7.83 (1H, d, <i>J</i> = 7.8 Hz, CH Ar), 8.01 (1H, d, <i>J</i> = 7.8 Hz, CH Ar), 8.34 (1H, d, <i>J</i> = 2.0 Hz, CH Ar) |
| EMAC8002e | ¹ H-NMR: (500 MHz, DMSO) 3.25 (3H, s, CH ₃), 6.68 (1H, s, CH thiazole), 7.29 (2H, s, NH ₂ , D ₂ O), 7.34 (2H, d, <i>J</i> = 8 Hz, CH Ar), 7.59 (1H, d, <i>J</i> = 8 Hz, CH Ar), 7.63 (1H, dd, <i>J</i> = 8.5, 2 Hz), 7.83 (2H, d, <i>J</i> = 8.5 Hz, CH Ar), 7.88 (1H, d, <i>J</i> = 2 Hz, CH Ar) |
| EMAC8002f | ¹ H-NMR: (300 MHz, DMSO) 3.46 (3H, s, CH ₃), 6.83 (1H, s, CH thiazole), 7.36 (2H, s, NH ₂ , D ₂ O), 7.44 (2H, d, <i>J</i> = 8.4 Hz, CH Ar), 7.58 (2H, d, <i>J</i> = 8.7 Hz, CH Ar), 7.63 (2H, dd, <i>J</i> = 8.4 Hz, CH Ar), 7.88 (2H, d, <i>J</i> = 8.5 Hz, CH Ar) |
| EMAC8002g | ¹ H-NMR: (300 MHz, DMSO) 3.55 (3H, s, CH ₃), 7.13 (1H, s, CH thiazole), 7.34 (1H, td, <i>J</i> = 8.4, 1.5 Hz, CH Ar), 7.45 (2H, s, NH ₂ , D ₂ O), 7.67–7.53 (4H, m, CH Ar), 7.93 (2H, d, <i>J</i> = 7.6 Hz, CH Ar) |
| EMAC8002h | ¹ H-NMR: (300 MHz, DMSO) 3.36 (3H, s, CH ₃), 6.61 (1H, s, CH thiazole), 7.17 (2H, d, <i>J</i> = 8.2 Hz, CH Ar), 7.25 (2H, s, NH ₂ , D ₂ O), 7.79 (2H, d, <i>J</i> = 8.5 Hz, CH Ar), 7.83 (2H, d, <i>J</i> = 8.7 Hz, CH Ar), 8.33 (2H, d, <i>J</i> = 8.0 Hz, CH Ar) |
| EMAC8002i | ¹ H-NMR: (500 MHz, DMSO) 3.59 (3H, s, CH ₃), 7.0 (1H, s, CH thiazole), 7.40 (2H, s, NH ₂), 7.43 (1H, m, CH Ar), 7.52 (2H, m, CH Ar), 7.56 (2H, d, <i>J</i> = 8 Hz, CH Ar), 7.66 (2H, d, <i>J</i> = 8 Hz, CH Ar), 7.75 (2H, m, CH Ar), 7.87 (2H, d, <i>J</i> = 8.5 Hz, CH Ar), 7.93 (2H, d, <i>J</i> = 8.5 Hz) |
| EMAC8002j | ¹ H-NMR: (300 MHz, DMSO) 2.40 (3H, s, CH ₃), 3.53 (3H, s, CH ₃), 6.91 (1H, s, CH thiazole), 7.46–7.36 (6H, m, CH Ar), 7.55 (2H, s, NH ₂ , D ₂ O), 7.92 (2H, d, <i>J</i> = 8.5 Hz, CH Ar) |
| EMAC8002k | ¹ H-NMR: (300 MHz, DMSO) 3.64 (3H, s, CH ₃), 3.96 (3H, s, OCH ₃), 6.98 (1H, s, CH thiazole), 7.23 (2H, d, <i>J</i> = 8.5 Hz, CH Ar), 7.54 (2H, s, NH ₂ , D ₂ O), 7.63–7.60 (4H, m, CH Ar), 8.04 (2H, d, <i>J</i> = 8.1 Hz, CH Ar) |
| EMAC8002l | ¹ H-NMR: (300 MHz, DMSO) 3.61 (3H, s, CH ₃), 7.15 (1H, s, CH thiazole), 7.48 (2H, s, NH ₂ , D ₂ O), 7.59 (5H, m, CH Ar), 7.67 (2H, d, <i>J</i> = 8.5 Hz, CH Ar), 7.97 (2H, d, <i>J</i> = 8.5 Hz, CH Ar) |
| EMAC8002m | ¹ H-NMR: (300 MHz, DMSO) 3.61 (3H, s, CH ₃), 7.15 (1H, s, CH thiazole), 7.48 (2H, s, NH ₂ , D ₂ O), 7.59 (5H, m, CH Ar), 7.67 (2H, d, <i>J</i> = 8.5 Hz, CH Ar), 7.97 (2H, d, <i>J</i> = 8.5 Hz, CH Ar) |

of the synthesised compounds are in agreement within $\pm 0.4\%$ of the theoretical values. TLC chromatography was performed using silica gel plates (Merck F 254), spots were visualised by UV light.

General procedure for the synthesis of compound EMAC8002a–m

Synthesis of 1-methyl-3-(4-sulfamoylthiethyl)thiourea

To an ethanolic solution of 4-aminobenzenesulphonamide (1 eq), methyl isothiocyanate (2 eq) was added dropwise. The mixture was heated under reflux until the completion of the reaction (10 h). The progress of the reaction was monitored by TLC (ethyl acetate/n-hexane 2/1). Then the reaction was cooled overnight in the fridge. A precipitate was formed which was collected by filtration under vacuum and crystallised from ethanol to afford the desired product.

Synthesis of 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamide

A mixture of 1-methyl-3-(4-sulfamoylphenyl)thiourea (1 eq) and α -halogenoketone (1 eq) was reacted in ethanol solution. Different reaction conditions have been employed. Thus, while in the presence of α -bromoketones the reaction temperature was kept between 30 and 50 °C, refluxing conditions were used when α -chloroketones were reacted. The mixture was reacted until completion (TLC, ethyl acetate/n-hexane 2/1). By cooling to room temperature, a precipitate was formed. The crude product was filtered and crystallised from the appropriate solvent. Analytical and spectral data of compounds EMAC8002a–m are reported in Tables 1 and 2.

Molecular modelling

The new ligand EMAC8002i was built by means of Maestro GUI⁵¹ in E configuration. Then a conformational search analysis was

performed using MCMM method allowing 5000 iterations in implicit solvent⁵².

Docking experiments were performed by means of Glide Quantum-Mechanical Polarised Docking^{53,54}. The crystallographic model with the best resolution was considered (pdb code 5MSA, 1.2 Å). The protein was prepared with Preparation Wizard protocol. The Grid box was centred on the co-crystallised ligand and all parameters were set up as default.

The best pose complex was then minimised to consider the induced fit phenomena and used to analyse the ligand-binding mode. 10,000 steps of the Polak-Ribier conjugate gradient (PRCG) minimisation method were conducted on the top ranked theoretical complex using OPLS_2005 force field⁵⁵.

The optimisation process was performed up to the derivative convergence criterion equal to 0.05 kcal/(mol*Å)⁻¹.

Biological activity

Carbonic anhydrase inhibition assay

The purification of cytosolic CA isoenzymes (CA I and CA II) was previously described with a simple one-step method by a Sepharose-4B-L tyrosine-sulphanilamide affinity chromatography⁵⁶.

The protein quantity in the column effluents was determined spectrophotometrically at 280 nm. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was applied with a Bio-Rad Mini Gel system Mini-PROTEINVR system (Hercules, CA), Bio-Rad Laboratories, Inc., China after purification of both CA isoenzymes. Briefly, it was performed in acrylamide for the running (10%) and the stacking gel (3%) contained SDS (0.1%), respectively. Activities of CA isoenzymes were determined according to a method by Verporte et al.⁵⁷. The increase in absorbance of the reaction medium was spectrophotometrically recorded at 348 nm. Also, the quantity of protein was determined at 595 nm according to the Bradford method⁵⁸. Bovine serum albumin was used as standard protein. The IC₅₀ values were obtained from activity (%) versus compounds plots⁵⁹. For calculation of K_i values, three different concentrations were used. The Lineweaver–Burk curves


were drawn and calculations were realised⁵⁹. The biological data are reported in Table 3.

Results and discussion

As a continuation of our ongoing research in the field of carbonic anhydrase and anticancer agents^{31,47–49,60}, we have synthesised a new series of 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamides, namely compounds **EMAC8002a–m**, to evaluate their activity and selectivity toward CA isozymes and to gain information on the structure–activity relationships of these derivatives. All the synthesised derivatives are characterised by the presence of a benzenesulphonamide moiety as zinc binder group, conjugated with the position 2 of a dihydrothiazole heterocyclic core. A methyl substituent is always present on the heterocyclic nitrogen atom, while a differently substituted aromatic ring occupies the position 4.


Table 3. Inhibition data towards hCA I, II, IX, and XII of compounds **EMAC8002 a–m**.

| Compound | R | K_i (nM) | | | |
|------------------|---------------------------------|------------|--------|--------|---------|
| | | hCA I | hCA II | hCA IX | hCA XII |
| EMAC8002a | 4-Br | 4457 | 45.8 | 58.1 | 778 |
| EMAC8002b | 4-Cl | 1548 | 13.1 | 1213 | 97.9 |
| EMAC8002c | 4-F | 4845 | 5.3 | 2482 | 40.0 |
| EMAC8002d | 3-NO ₂ | 2456 | 17.8 | 1821 | 271 |
| EMAC8002e | 2,4-Cl | >10,000 | 398 | 1605 | 10.5 |
| EMAC8002f | 4-CN | 2650 | 17.9 | 2064 | 94.7 |
| EMAC8002g | 2,4-F | >10,000 | 37.7 | 1648 | 9.0 |
| EMAC8002h | 4-NO ₂ | 2239 | 19.9 | 142 | 9.5 |
| EMAC8002i | 4-C ₆ H ₅ | 8910 | 503 | 1389 | 9.5 |
| EMAC8002j | 4-CH ₃ | 2603 | 4.5 | 23.3 | 3.1 |
| EMAC8002k | 4-OCH ₃ | 5580 | 3.8 | 25.4 | 4.6 |
| EMAC8002l | // | 1650 | 30.3 | 1874 | 36.9 |
| EMAC8002m | H | 2305 | 5.3 | 620 | 9.4 |
| AAZ | // | 250 | 12 | 25 | 5.7 |



The synthetic procedure to obtain compounds **EMAC8002a–m** is depicted in Scheme 1. Briefly, it consists of two steps: the synthesis of the 3-methyl-1-(4-sulfamoylphenyl)thiourea (1) by reaction of the 4-aminobenzensulfonamide with methyl isocyanate. The second step is the formation of the 4-aryl dihydrothiazole nucleus. It was accomplished by reacting 1 with the appropriate α -halogenoketone in ethanol solution. **EMAC8002a–m** were characterised by means of analytical and spectroscopic methods (Tables 1 and 2) and then submitted to enzymatic evaluation toward hCA I, II, IX, and XII.

The results are summarised in Table 3. Accordingly with our previous observations with similar derivatives, none of the **EMAC8002** compounds was active toward hCA I isozyme. On the contrary, when isozymes II, IX, and XII are investigated, some consideration regarding the structure–activity relationships could be done. When compounds **EMAC8002** are tested on hCA II, the introduction of a halogen atom, in position 4 of the phenyl moiety, in position 4 of the dihydrothiazole ring, appeared beneficial for the activity. However, the larger is the atomic radius of the halogen, the lower the activity. So far, the K_i values are in the following order: 4-F (**EMAC8002c**) 5.3 nM < 4-Cl (**EMAC8002b**) 13.1 nM < 4-Br (**EMAC8002a**) 45.8 nM. A similar behaviour was observed in the case of hCA XII: 4-F (**EMAC8002c**) 5.3 nM < 4-Cl (**EMAC8002b**) 13.1 nM < 4-Br (**EMAC8002a**) 45.8 nM. On the contrary, when the same compounds were evaluated on hCA IX, a totally reversed trend was observed. In fact, the larger is the halogen atom the higher the activity. Accordingly, the K_i values are 4-F (**EMAC8002c**) 2482 nM > 4-Cl (**EMAC8002b**) 1213 nM > 4-Br (**EMAC8002a**) 58.1 nM. The introduction of a second halogen atom in the position 2 of the phenyl ring is beneficial only for the activity toward the hCA XII isoform. Thus, in the case of compounds **EMAC8002e** (2,4-Cl) and **EMAC8002g** (2,4-F) the K_i values are 10.5 and 9.0 nM, respectively. Accordingly, when the 4-Cl derivative (**EMAC8002b**) is compared with the 2,4-diCl one (**EMAC8002e**), a 9-fold gain in potency toward the hCA XII isozyme was observed. Similarly, a 4-fold increase in potency toward hCA XII was observed when 4-F (**EMAC8002c**) and 2,4-diF (**EMAC8002g**) are compared. On the contrary, the inverse was observed when hCA II isozyme is considered. A decrease in the activity of 7 folds was observed when 2,4-diF (**EMAC8002g**) was compared with 4-F (**EMAC8002c**). Analogously a decrease of the inhibition potency of 30 folds was measured when 2,4-diCl (**EMAC8002e**) was compared with 4-Cl (**EMAC8002b**). On these bases, we can summarise that by introducing specific halogen atoms in specific positions of the 4-phenyl ring, it is possible to



Ar = 4-BrPh, 4-ClPh, 4-FPh, 3-NO₂Ph, 2,4-ClPh, 4-CNPh, 2,4-FPh, 4-NO₂Ph, 4-C₆H₅Ph, 4-CH₃Ph, 4-OCH₃Ph, thiophen, Ph

Scheme 1. Synthetic pathway to compounds **EMAC8002a–m**. Reagents and conditions: (i) ethanol, methylisothiocyanate; (ii) ethanol, α -halogenoarylketone.




Figure 2. (a) ROESY spectrum of compound **EMAC8002i**; (b) Partial ROESY spectrum of compound **EMAC8002i**.

modulate the activity toward different hCA isozymes. The introduction of a nitro group is tolerated both in the 3 and 4 position of the phenyl ring when hCA II is considered. On the contrary, when the activity on hCA XII is measured, the introduction of the nitro group is only tolerated in the 4 position. The introduction of electron-donating groups such as methyl or methoxy, as in

compounds **EMAC8002j** and **EMAC8002k**, respectively, led to most active compounds when hCA II, IX, and XII are considered. Unfortunately, none of the two substitutions led to selective compounds. The presence of a nitrile in the position 4 as in the case of compound **EMAC8002f**, is generally detrimental for the activity, but for hCAII, where this substitution is tolerated. By




Figure 3. Three-dimensional representation of the putative binding mode as obtained by docking experiments of: (a) **EMAC8002-i** and (b) relative 2D representation of the complex stabilising interactions with the residues of the binding site.

introducing a biphenyl group in the position 4 of the dihydrothiazole, the most selective compound toward hCA XII (**EMAC8002i**) was obtained, with a selective index hCA II/hCA XII higher than 52. When compared with 4-phenyldihydrothiazole (**EMAC8002m**), the isosteric introduction of a thiophene-2-yl moiety in the position 4 of the dihydrothiazole (**EMAC8002i**) was beneficial only for the activity toward hCA I, although with high values of K_i .

These results, together with our previous findings, indicate that the 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamide scaffold could be rationally and efficiently decorated in order to achieve potent and selective hCA inhibitors.

The possible formation of both E and Z diastereoisomers along the C=N double bond was investigated by 2D NMR experiments. To this end, the ROESY spectrum of the most interesting compound of the series **EMAC8002i** was recorded (Figure 2). This derivative showed good selectivity toward hCA XII and inhibitory activity toward this enzyme in the low nM range. ROESY cross-peak from the methyl group at δ_H 3.59 (3H, s) to the aromatic protons H-2 and H-3 at δ_H 7.56 (2H, d, $J=8$ Hz) permitted to assign the configuration around the double bond as E. In fact, examination of a molecular model confirms that, in the case of (Z) configuration, H-2 and H-3 aromatic protons would be too far to the methyl group and correlation should not be observed. Analogous experiments were performed along the full series of compounds and, as expected, the (E) configuration was assigned to all derivatives.

In order to predict the binding mode of compound **EMAC8002i**, a molecular docking experiment was performed. The most selective was well docked into the catalytic site of CA XII with binding energies of -10.194 kcal/mol. The complex has been energy minimised and the putative binding mode is depicted in Figure 3.

The ligand well fit into the binding pocket. The benzenesulphonamide moiety tightly interacts with the deep cavity and the Zn (II) ion, being stabilised by the metal chelation and an array of hydrogen bonds with the residues around the ion: Thr198, Thr199, and His117. Furthermore, the nitrogen atom of the aminobenzenesulphonamide moiety interacts with Gln89. Moreover, the substituent in the position 4 of the thiazolino portion interacts with the external part of the cavity. The analysis of the putative

binding mode highlighted the presence of extra space in correspondence of the N methyl substituent which will be exploited to increase the ligand complementarity and probably its activity and selectivity.

Conclusions

We have designed and synthesised a series of 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamides and evaluate their activity on hCA I, II, IX, and XII isozymes. While these derivatives were weak inhibitors of the hCA I isoform, interestingly, the nature and substitution pattern of the aromatic group in the position 4 of the dihydrothiazole core was relevant for the activity and the selectivity between the hCA II and XII isoforms. Nevertheless, we observed that the introduction of a 4-methylphenyl or a 4-methoxyphenyl moiety in the position 4 of the dihydrothiazole ring is beneficial for the activity toward hCA II, IX, and XII isozymes. These data prompted us to further investigate on these scaffolds in order to optimise both the activity and the isozyme selectivity.

Acknowledgements

The authors wish to acknowledge the “Ufficio Valorizzazione dei Risultati della Ricerca” of Sardegna Ricerche Technological Park, Pula (CA) – Italy. The authors also thank the COST action CA15135 (Multitarget Paradigm for Innovative Ligand Identification in the Drug Discovery Process MuTaLig) for support.

Disclosure statement

No potential conflict of interest was reported by the authors.

ORCID

Simona Distinto <https://orcid.org/0000-0003-1620-6225>
 Rita Meleddu <https://orcid.org/0000-0003-1629-7454>
 Francesco Ortuso <https://orcid.org/0000-0001-6235-8161>
 Lisa Sequeira <https://orcid.org/0000-0002-5801-9455>

Andrea Angeli  <http://orcid.org/0000-0002-1470-7192>
 Clemente Capasso  <http://orcid.org/0000-0003-3314-2411>
 Stefano Alcaro  <https://orcid.org/0000-0002-0437-358X>
 Claudiu T. Supuran  <http://orcid.org/0000-0003-4262-0323>
 Elias Maccioni  <https://orcid.org/0000-0003-2175-2802>

References

- Lott WA, Bergeim FH. 2-(p-Aminobenzenesulfonamido)-thiazole: a new chemotherapeutic agent. *J Am Chem Soc* 1939;61:3593–4.
- Ball AP, Geddes AM, Davey PG, et al. Clavulanic acid and amoxicillin: a clinical, bacteriological, and pharmacological study. *Lancet* 1980;1:620–3.
- Oslob JR, Allen DA, Baskaran S, et al. Discovery of a potent and selective aurora kinase inhibitor. *Bioorg Med Chem Lett* 2008;18:4880–4.
- Claussen CA, Long EC. Nucleic acid recognition by metal complexes of bleomycin. *Chem Rev* 1999;99:2797–816.
- Tricot G, Jayaram HN, Weber G, et al. Tiazofurin: biological effects and clinical uses. *Int J Cell Clon* 1990;8:161–70.
- Hara M, Asano K, Kawamoto I, et al. Leinamycin, a new anti-tumor antibiotic from streptomyces: producing organism, fermentation and isolation. *J Antibiot* 1989;42:1768–74.
- Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. *Proc Natl Acad Sci USA* 1995;92:2484–8.
- Meleddu R, Distinto S, Corona A, et al. Isatin thiazoline hybrids as dual inhibitors of HIV-1 reverse transcriptase. *J Enzyme Inhib Med Chem* 2017;32:130–6.
- Meleddu R, Distinto S, Corona A, et al. (3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase. *Eur J Med Chem* 2015;93:452–60.
- Corona A, Meleddu R, Esposito F, et al. Ribonuclease H/DNA polymerase HIV-1 reverse transcriptase dual inhibitor: mechanistic studies on the allosteric mode of action of isatin-based compound RMNC6. *PLoS One* 2016;11:e0147225.
- Distinto S, Maccioni E, Meleddu R, et al. Molecular aspects of the RT/drug interactions. perspective of dual inhibitors. *Curr Pharm Design* 2013;19:1850–9.
- Distinto S, Esposito F, Kirchmair J, et al. Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach. *Eur J Med Chem* 2012;50:216–29.
- Meleddu R, Distinto S, Corona A, et al. Exploring the thiazole scaffold for the identification of new agents for the treatment of fluconazole resistant *Candida*. *J Enzyme Inhib Med Chem* 2016;31:1672–7.
- Ojika M, Suzuki Y, Tsukamoto A, et al. Cystothiazoles A and B, new bithiazole-type antibiotics from the myxobacterium *Cystobacter fuscus*. *J Antibiot* 1998;51:275–81.
- Marquez BL, Watts KS, Yokochi A, et al. Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly. *J Nat Prod* 2002;65:866–71.
- Costa FH, Rosso AL, Maultasch H, et al. Depression in Parkinson's disease: diagnosis and treatment. *Arquivos de Neuro-Psiquiatria* 2012;70:617–20.
- Chimenti F, Maccioni E, Secci D, et al. Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones. *J Med Chem* 2008;51:4874–80.
- Willcox RR. Treatment of vaginal trichomoniasis with aminotroazole and trichomycin given orally. *Gynaecologia* 1960;149:122–7.
- Domsic JF, Avvaru BS, Kim CU, et al. Entrapment of carbon dioxide in the active site of carbonic anhydrase II. *J Biol Chem* 2008;283:30766–71.
- Boron WF. Evaluating the role of carbonic anhydrases in the transport of HCO₃⁻-related species. *Biochimica et Biophysica Acta* 2010;1804:410–21.
- Geers C, Gros G. Carbon dioxide transport and carbonic anhydrase in blood and muscle. *Physiol Rev* 2000;80:681–715.
- Horie K, Kawakami K, Fujita Y, et al. Exosomes expressing carbonic anhydrase 9 promote angiogenesis. *Biochem Biophys Res Commun* 2017;492:356–61.
- Supuran CT. Structure and function of carbonic anhydrases. *Biochem J* 2016;473:2023–32.
- McIntyre A, Hulikova A, Ledaki I, et al. Disrupting hypoxia-induced bicarbonate transport acidifies tumor cells and suppresses tumor growth. *Cancer Res* 2016;76:3744–55.
- Jiang J, Zhao JH, Wang XL, et al. Correlation between carbonic anhydrase IX (CA-9), XII (CA-12) and hypoxia inducible factor-2 α (HIF-2 α) in breast cancer. *Neoplasma* 2015;62:456–63.
- Imtaiyaz Hassan M, Shajee B, Waheed A, et al. Structure, function and applications of carbonic anhydrase isozymes. *Bioorg Med Chem* 2013;21:1570–82.
- Supuran CT. Inhibition of carbonic anhydrase IX as a novel anticancer mechanism. *World J Clin Oncol* 2012;3:98–103.
- Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. *Nat Rev Drug Discov* 2011;10:767–77.
- Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. *Cancer Metast Rev* 2007;26:299–310.
- Zhou Y, Mokhtari RB, Pan J, et al. Carbonic anhydrase II mediates malignant behavior of pulmonary neuroendocrine tumors. *Am J Respir Cell Mol Biol* 2015;52:183–92.
- Meleddu R, Maccioni E, Distinto S, et al. New 4-[(3-cyclohexyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzene-1-sulphonamides, synthesis and inhibitory activity toward carbonic anhydrase I, II, IX, XII. *Bioorg Med Chem Lett* 2015;25:3281–4.
- Eldehna WM, Fares M, Ceruso M, et al. Amido/ureidosubstituted benzenesulphonamides-isatin conjugates as low nanomolar/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII. *Eur J Med Chem* 2016;110:259–66.
- Ceruso M, Bragagni M, AlOthman Z, et al. New series of sulphonamides containing amino acid moiety act as effective and selective inhibitors of tumor-associated carbonic anhydrase XII. *J Enzyme Inhib Med Chem* 2015;30:430–4.
- Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. *J Enzyme Inhib Med Chem* 2012;27:759–72.
- Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. *Nat Rev Drug Discov* 2008;7:168–81.
- Supuran CT. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. *Expert Opin Ther Pat* 2003;13:1545–50.

37. Picard F, Deshaies Y, Lalonde J, et al. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. *Obes. Res* 2000;8:656–63.
38. Maresca A, Temperini C, Pochet L, et al. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. *J Med Chem* 2010;53:335–44.
39. Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. *J Am Chem Soc* 2009;131:3057–62.
40. Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? *J Enzyme Inhib Med Chem* 2016;31:345–60.
41. De Simone G, Alterio V, Supuran CT. Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors. *Expert Opin Drug Discov* 2013;8:793–810.
42. Alterio V, Di Fiore A, D'Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? *Chem Rev* 2012;112:4421–68.
43. Pala N, Micheletto L, Sechi M, et al. Carbonic anhydrase inhibition with benzenesulphonamides and tetrafluorobenzenesulphonamides obtained via click chemistry. *ACS Med Chem Lett* 2014;5:927–30.
44. Suthar SK, Bansal S, Lohan S, et al. Design and synthesis of novel 4-(4-oxo-2-arylthiazolidin-3-yl)benzenesulphonamides as selective inhibitors of carbonic anhydrase IX over I and II with potential anticancer activity. *Eur J Med Chem* 2013;66:372–9.
45. Guzel-Akdemir O, Akdemir A, Karali N, et al. Discovery of novel isatin-based sulphonamides with potent and selective inhibition of the tumor-associated carbonic anhydrase isoforms IX and XII. *Org Biomol Chem* 2015;13:6493–9.
46. Ibrahim HS, Abou-Seri SM, Tanc M, et al. Isatin-pyrazole benzenesulphonamide hybrids potently inhibit tumor-associated carbonic anhydrase isoforms IX and XII. *Eur J Med Chem* 2015;103:583–93.
47. Melis C, Meleddu R, Angeli A, et al. Isatin: a privileged scaffold for the design of carbonic anhydrase inhibitors. *J Enzyme Inhib Med Chem* 2017;32:68–73.
48. Bianco G, Meleddu R, Distinto S, et al. N-Acylbenzenesulphonamide dihydro-1,3,4-oxadiazole hybrids: seeking selectivity toward carbonic anhydrase isoforms. *ACS Med Chem Lett* 2017;8:792–6.
49. Meleddu R, Distinto S, Cottiglia F, et al. Tuning the dual inhibition of carbonic anhydrase and cyclooxygenase by dihydrothiazole benzenesulphonamides. *ACS Med Chem Lett* 2018;9:1045.
50. Melis C, Distinto S, Bianco G, et al. Targeting tumor associated carbonic anhydrases IX and XII: highly isozyme selective coumarin and psoralen inhibitors. *ACS Med Chem Lett* 2018;9:725–9.
51. Schrödinger LLC, New York, NY. 2018.
52. Mohamadi F, Richards NG, Guida WC, et al. MacroModel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. *J Comput Chem* 1990;11:440–67.
53. Cho AE, Guallar V, Berne BJ, et al. Importance of accurate charges in molecular docking: quantum mechanical/molecular mechanical (QM/MM) approach. *J Comput Chem* 2005;26:915–31.
54. Chung JY, Hah JM, Cho AE. Correlation between performance of QM/MM docking and simple classification of binding sites. *J Chem Inform Model* 2009;49:2382–7.
55. Jorgensen WL. OPLS force fields. In Schleyer PvR, ed. *Encyclopedia of Computational Chemistry*. New York: Wiley; 1998:1986–9.
56. Akbaba Y, Akıncıoğlu A, Göçer H, et al. Carbonic anhydrase inhibitory properties of novel sulphonamide derivatives of aminoindanes and aminotetralins. *J Enzyme Inhib Med Chem* 2014;29:35–42.
57. Verpoorte JA, Mehta S, Edsall JT. Esterase activities of human carbonic anhydrases B and C. *J Biol Chem* 1967;242:4221–9.
58. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976;72:248–54.
59. Senturk M, Gulcin I, Beydemir S, et al. *In vitro* inhibition of human carbonic anhydrase I and II isozymes with natural phenolic compounds. *Chem Biol Drug Des* 2011;77:494–9.
60. Meleddu R, Petrikaite V, Distinto S, et al. Investigating the anticancer activity of isatin/dihydropyrazole hybrids. *ACS Med Chem Lett* 2018;10:571–6.